Free Trial

Avacta Group (LON:AVCT) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Avacta Group logo with Medical background

Key Points

  • Avacta Group shares have surpassed their 200-day moving average, indicating a potential bullish trend in the stock market performance.
  • The company reported a negative EPS of GBX (8.54) for its last quarter, projecting a challenging financial outlook with an expected EPS of -9.90 for the current year.
  • Avacta Group has a market capitalization of £172.38 million and a high debt-to-equity ratio of 52.53, which may raise concerns about its financial leverage.
  • Need better tools to track Avacta Group? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Avacta Group Plc (LON:AVCT - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 37.67 ($0.51) and traded as high as GBX 54.50 ($0.73). Avacta Group shares last traded at GBX 48 ($0.65), with a volume of 2,916,859 shares trading hands.

Avacta Group Stock Down 6.2%

The stock has a market capitalization of £161.84 million, a PE ratio of -5.48 and a beta of 1.12. The company's fifty day moving average price is GBX 36.58 and its 200-day moving average price is GBX 37.54. The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53.

Avacta Group (LON:AVCT - Get Free Report) last issued its quarterly earnings data on Friday, June 6th. The biotechnology company reported GBX (8.54) (($0.11)) EPS for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. Analysts forecast that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

About Avacta Group

(Get Free Report)

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

Featured Stories

Should You Invest $1,000 in Avacta Group Right Now?

Before you consider Avacta Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avacta Group wasn't on the list.

While Avacta Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines